133 related articles for article (PubMed ID: 25841397)
21. Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer.
Du XL; Zhang Y; Hardy D
Cancer Causes Control; 2016 May; 27(5):695-707. PubMed ID: 27059219
[TBL] [Abstract][Full Text] [Related]
22. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
Shameem R; Hamid MS; Wu S
Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
[TBL] [Abstract][Full Text] [Related]
23. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events.
Fandrey J; Dicato M
Oncologist; 2009; 14 Suppl 1():34-42. PubMed ID: 19762515
[TBL] [Abstract][Full Text] [Related]
24. Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: a meta-analysis of individual patient data.
Fokkema ML; van der Meer P; Rao SV; Belonje AM; Ferrario M; Hillege HL; Katz SD; Lipšic E; Ludman AJ; Ott I; Prunier F; Choi DJ; Toba K; van Veldhuisen DJ; Voors AA
Am Heart J; 2014 Sep; 168(3):354-362.e2. PubMed ID: 25173548
[TBL] [Abstract][Full Text] [Related]
25. Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis.
Marchetti C; De Felice F; Palaia I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2016 Mar; 99():123-8. PubMed ID: 26748593
[TBL] [Abstract][Full Text] [Related]
26. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.
Ludwig H; Crawford J; Osterborg A; Vansteenkiste J; Henry DH; Fleishman A; Bridges K; Glaspy JA
J Clin Oncol; 2009 Jun; 27(17):2838-47. PubMed ID: 19380447
[TBL] [Abstract][Full Text] [Related]
27. Tumor progression associated with erythropoiesis-stimulating agents.
Newland AM; Black CD
Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
[TBL] [Abstract][Full Text] [Related]
28. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
[TBL] [Abstract][Full Text] [Related]
29. Risks of Venous Thromboembolism, Stroke, Heart Disease, and Myelodysplastic Syndrome Associated With Hematopoietic Growth Factors in a Large Population-Based Cohort of Patients With Colorectal Cancer.
Du XL; Zhang Y
Clin Colorectal Cancer; 2015 Dec; 14(4):e21-31. PubMed ID: 26119923
[TBL] [Abstract][Full Text] [Related]
30. Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients.
Tonia T; Bohlius J
Cancer Treat Res; 2011; 157():217-38. PubMed ID: 21052959
[TBL] [Abstract][Full Text] [Related]
31. The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty: a meta-analysis of randomized clinical trials.
Alsaleh K; Alotaibi GS; Almodaimegh HS; Aleem AA; Kouroukis CT
J Arthroplasty; 2013 Oct; 28(9):1463-72. PubMed ID: 23528548
[TBL] [Abstract][Full Text] [Related]
32. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.
Bohlius J; Bohlke K; Castelli R; Djulbegovic B; Lustberg MB; Martino M; Mountzios G; Peswani N; Porter L; Tanaka TN; Trifirò G; Yang H; Lazo-Langner A
J Clin Oncol; 2019 May; 37(15):1336-1351. PubMed ID: 30969847
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy-induced anemia: the story of darbepoetin alfa.
Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M
Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876
[TBL] [Abstract][Full Text] [Related]
34. Anemia management in oncology and hematology.
Spivak JL; Gascón P; Ludwig H
Oncologist; 2009; 14 Suppl 1():43-56. PubMed ID: 19762516
[TBL] [Abstract][Full Text] [Related]
35. Erythropoiesis stimulating agents, thrombosis and cancer.
Barbera L; Thomas G
Radiother Oncol; 2010 Jun; 95(3):269-76. PubMed ID: 20219259
[TBL] [Abstract][Full Text] [Related]
36. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.
Glaspy J; Crawford J; Vansteenkiste J; Henry D; Rao S; Bowers P; Berlin JA; Tomita D; Bridges K; Ludwig H
Br J Cancer; 2010 Jan; 102(2):301-15. PubMed ID: 20051958
[TBL] [Abstract][Full Text] [Related]
37. Venous thromboembolic events and erythropoiesis-stimulating agents: an update.
Dicato M
Oncologist; 2008; 13 Suppl 3():11-5. PubMed ID: 18458119
[TBL] [Abstract][Full Text] [Related]
38. Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis.
Hedenus M; Osterborg A; Tomita D; Bohac C; Coiffier B
Leuk Lymphoma; 2012 Nov; 53(11):2151-8. PubMed ID: 22497574
[TBL] [Abstract][Full Text] [Related]
39. Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma.
Horváth-Puhó E; Suttorp MM; Frederiksen H; Hoekstra T; Dekkers OM; Pedersen L; Cannegieter SC; Dekker FW; Sørensen HT
Clin Epidemiol; 2018; 10():1371-1380. PubMed ID: 30310329
[TBL] [Abstract][Full Text] [Related]
40. Effect of erythropoiesis-stimulating agents on breast cancer patients: a meta-analysis.
Wu T; Tong Z; Ren T; Xie D; Sun X
Clin Exp Med; 2023 Sep; 23(5):1501-1513. PubMed ID: 36315312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
